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Abstract
URG7 is an anti-apoptotic protein which consists of 99 amino acid residues up regulated by antigen x during the
HBV infection. The first 74 amino acids are identical to those of the multidrug resistance protein 6 (MRP6), while the
amino acid residues from 75 to 99 are specific for URG7 protein. Immuno-informatics tools and secondary structure
analysis were carried out to identify the antigenic properties of this URG7 sequence. The 75-99 peptide was
synthesized by the solid-phase method, structurally characterized by CD spectroscopy and conjugated to a protein
carrier. New Zealand white rabbits were immunized and sera were tested for anti-peptide specific antibodies by
ELISA and western blot analysis. Finally ELISA test with human sera was performed.
Rabbits immunized with the 75-99 peptide produce antibodies that recognize both the 75-99 peptide and the
URG7 recombinant polypeptide. Moreover, both antigens allowed for the detection of the anti-URG7 antibodies in
sera of healthy and HBV infected subjects although with a different discriminant threshold. Our data suggested that
peptide ELISA assay against the specific sequence of the URG7 protein allows with good sensitivity and specificity
for the detection of anti-URG7 antibodies in sera from HBV infected patients.
Keywords: ELISA; Immunogenic peptide; Hepatitis B virus;
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Introduction
In the hepatocytes infected by the hepatitis B virus (HBV), the
hepatitis B virus X (HBx) protein has a crucial role in the pathogenesis
of chronic infection and the development of hepatocellular carcinoma
(HCC). HBx trans-activates a large number of signaling pathways and
cellular genes that are involved in oncogenesis, proliferation,
inflammation and immune responses [1-3], regulates protein stability
via interaction with proteasome subunits [4] and more recently was
reported to be able to regulate microRNA expression [5]. One of the
cellular genes whose expression is up-regulated by HBx is the Up-
Regulated Gene clone 7 (URG7). This gene encodes a protein of 99
amino acids which is highly homologous with the amino terminal of
the multidrug resistance protein 6 (MRP6) [6,7]. This protein belongs
to the ABC family of transport proteins (ATP Binding Cassette) and is
encoded by the ABCC6 gene, whose mutations are associated with the
genetic disease Pseudoxanthoma elasticum [8,9].
Studies carried out on HepG2 cells transfected with the URG7 gene
indicated that the encoded protein stimulated the growth of cells in
serum free medium and partially protected cells from anti-Fas
mediated killing by means of an anti-apoptotic activity mediated by
caspases 3 and 8 [10]. Moreover, URG7 activates the transduction
pathway of the PI3K/AKT signal and β-catenin too, suggesting that it
contributes to sustaining chronic virus infection which later plays a
role in the development of HCC [11]. URG7 expressed in HepG2 cells
localizes in the endoplasmic reticulum with an Nlumen-Ccytosol
orientation [12,13]. Actually, little information is available on the
structural properties of the URG7 protein: circular dichroism and
fluorescence spectroscopy studies showed that the His-URG7
polypeptide expressed in Escherichia coli assumes secondary
structures in non-polar solvents and in micellar solutions of SDS,
reasonable with its localization within the endoplasmic reticulum [14].
Some of the HBx associated up-regulated genes (URGs) trigger
corresponding antibodies in the sera of patients at the early stage
tumorigenesis, suggesting that the anti-URGs antibodies may have
diagnostic/prognostic utility among patients at high risk for the
development of cirrhosis and/or HCC. In particular, in the serum of
infected patients who will develop HCC, it was found that various
combinations of different anti-URG antibodies, either alone or in
combination with existing markers, may increase the chances of
identifying patients at high risk for cirrhosis and/or HCC or with early
cirrhosis and/or HCC [15,16]. However, it is noteworthy that the
peptides used in these previous ELISA tests spanned the amino acid
(aa) sequences 12-25 and 56-70 of the URG7 protein, actually
corresponding to the amino acid sequence of the MRP6 [15].
In the present work, we report the antigenic and structural features
of the synthetic peptide corresponding to the unique sequence aa75-99
belonging to the URG7 protein to develop an ELISA test for
specifically evaluating the presence of anti-URG7 antibodies in the
serum of patients affected by hepatitis virus infection.
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Materials and Methods
Peptide synthesis and structural analysis
The portion of the peptide spanning aa75-99
(75AAIPGSLEPGNVRGRQGTGWNLVKS99) and corresponding to
the last 25 amino acids of the URG7 protein was synthesized on a
Pioneer PerSeptive Biosystem synthesizer by the solid-phase method
using Fmoc chemistry. Coupling reagents (0.5 M PyBop/DMF and 1.0
M DIPEA/DMF) were used with a four-fold excess of amino acid. A
TFA/H2O/thioanisole/phenol/isopropyl silane (88%, 3%, 3%, 4%, and
2%) mixture was used for the final deprotection and cleavage of the
peptides. Crude peptide was precipitated in cold diethyl ether, then
lyophilized and finally purified using reverse-phase HPLC on a
Phenomenex C18 column (2.5 × 300 mm, 5 μm particles) using a
gradient of acetonitrile/water in 0.1% TFA [17]. The molecular mass of
the peptide was confirmed by mass spectroscopy. Protein
concentration was determined by measuring the optical absorbance at
280 nm using 5500 M-1cm-1 as the extinction coefficient calculated
from the amino acid composition.
CD spectra were recorded on a Jasco J-815 CD Spectrometer with a
Xenon 250W lamp and peptide solution (50 µM in 10 mM phosphate
buffer pH 6). The acquisition was carried out in a cylindrical quartz
thermostated cell with an optical path of 1 mm, in the spectral range of
190-250 nm, with a scanning speed of 100 nm/min, a bandwidth of 1
nm, a time-constant of 0.5 s, a sensitivity of 20 mdeg and a total
number of 16 accumulations for each spectrum. The baseline spectrum
of the solvent was subtracted and peptide spectrum was smoothed
using the Fourier transform. Data were expressed in terms of the molar
ellipticity per residue in units of deg × cm2 × dmol-1. Analysis of the
CD spectrum for the evaluation of secondary structure content was
performed with DICHROWEB using the CONTIN algorithm [18].
Indirect ELISA with antiserum anti-peptide
The IEBD server (www.iedb.org) was used to predict the antigenic
propensity of the URG7 protein [19]. The synthesized peptide
conjugated to the carrier protein ovalbumin via an N-terminal cysteine
residue [20] was mixed in a 1:1 ratio with alum and finally used to
immunize two male New Zealand white rabbits according to the
standard procedure to obtaining a polyclonal antibody (PRIMM srl,
Milan). 96-well microtiterplates (NUNC Polysorp) incubated with 5%
glutaraldehyde for 1 h at room temperature (RT) were coated with
synthetic peptide (1 µg/well) in PBS (phosphate buffered saline) pH 7.6
or with recombinant His-URG7 polypeptide [14] (200 ng/well) in 70%
TFE overnight at 4ºC. Controls were obtained by performing the assay
in wells containing PBS without peptide and in wells coated with the
recombinant His-URG7 polypeptide that recognized a commercially
available monoclonal anti-polyHistidine-Peroxidase (Sigma). After
washing with PBS-Tween 0.05%, the wells were incubated with 5%
(w/v) non-fat milk (NFM) in PBS for 2 h at 37ºC. After washing, rabbit
purified antibodies were serially diluted in 1% NFM in PBS and
dispensed into the wells. The plates were incubated for 1 h at RT and
then washed. Anti-rabbit–HRP conjugate (Santa Cruz Biotechnology,
USA) diluted 1:5000 in 1% NFM in PBS was added and after
incubation for 1 h at RT the plates were washed as above. The
chromogen development was mediated by the addition of freshly
prepared substrate solution (o-phenylenediamine dihydrochloride,
Sigma). The reaction was stopped by the addition of 1N sulfuric acid
and the OD was measured at 450 nm on a microplate reader.
Western blot analysis
Recombinant His-URG7 polypeptide was resolved on a 15%
polyacrylamide SDS gel and electroblotted onto nitrocellulose
membranes. Membranes were blocked with 1% NFM at RT for 1 h and
incubated with rabbit antibodies against the 75-99 peptide at RT for 1
h. Subsequently, HRP-conjugated secondary antibody (1:1000) was
added and the membranes were incubated for 1 h at RT and, finally,
developed using enhanced chemiluminescence reagents (ECL,
Promega).
Indirect ELISA with human sera
To evaluate the presence of anti-URG7 antibodies in human sera,
blood samples were obtained, after informed consent, from 12 healthy
subjects (8 females of mean age 39 ± 9 and 4 males of mean age 43 ± 4)
with no serologic evidence of HBV infection or biochemical evidence
of liver disease and 30 HBV infected patients (3 females of mean age 72
± 16 and 27 males of mean age 51 ± 11) positives both for HBsAg and
HBV DNA and with alanine aminotransferase (ALT) >40 U/L. 96-well
microtiterplates were coated with antigens as described above. After
overnight incubation with human sera diluted 1:50 in 1% NFM in PBS,
anti-human IgG-HRP conjugate (Santa Cruz Biotechnology, USA) as a
secondary antibody was used. All tests were performed in triplicate
and appropriate negative controls were also made (evaluation of the
absorbance in the wells incubated with only the patient's serum and
secondary antibodies but without antigen). Each serum sample was
tested blindly.
Statistical analysis
For statistical evaluations of significant differences, data were
analyzed by using STATA for Windows Software®, Release 12, Stata
Corp, (http://www.stata.com/) Box-plots display variations among
populations and where outliers are located. The main statistics, as
means and standard deviations, summarize the characteristics of the
data. Response means between markers were compared by using a T-
paired test for the random sample from healthy subjects and a
Kolmogorov-Smirnov test for the random sample from sick subjects.
The Shapiro-Wilk test was used to check if the response data have a
Gaussian distribution.
Results and Discussion
The increase of anti-URG7 antibodies in patients infected by the
hepatitis B virus is related to a neoplastic transformation in
hepatocellular carcinoma (HCC) [15,16]. For this purpose it is
essential to have a sensitive and specific method for the determination
of these antibodies. The simplest method for the determination of
antibodies in serum is the ELISA test. Although it has been shown [16]
that there is a statistically significant relationship between the presence
of anti-URG7 antibodies against antigens 12-25 and 56-70 of the
URG7 protein and the onset of dysplastic nodules, it cannot be
excluded that these antibodies were produced by the corresponding
polypeptide sequences from the MRP6 protein. In order to obtain a
specific URG7 antigen, the 75-99 peptide was synthesized and purified
by reverse-phase liquid chromatography. Using the B-cell epitope
prediction tool from the IEDB analysis resource (http://
tools.immuneepitope.org/tools/bcell/iedb_input) the antigenic propensity of
the URG7 protein was determined. Different methods [21-26] which
are based on parameters such as hydrophilicity, flexibility, accessibility,
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turns, exposed surface and polarity of the polypeptide chain help to
identify a linear epitope in the aa 75-99 region (Figure 1).
Figure 1: Prediction analysis of the antigenic propensity of the URG7 protein. A: Alignment of the URG7 sequence with the first 99aa residues
of the ABCC6 protein. B: Potential linear peptides predicted to be antigenic determinants. Linear B-cell epitope prediction using the
prediction tools of IEDB corresponding to the amino acid residues 12-25, 56-70 and 75-99 (residues in the boxes). The red letters show those
sequences which can act as B-cell epitopes to elicit humoral immune response according to (a) [21] (b) [22] (c) [23] (d) [24] (e) [25] (f) [26].
The average antigenic index for epitopes by Chou & Fasman method was 0.991, by Emini method was 1, by Karplus and Schulz method was
0.984, by Kolaskar and Tongaonkar method was 1.044, by Parker method was 0.490 and by Pontoppidan method was -0.009.
Figure 2: CD spectra of the 75-99 URG7 peptide. A peptide solution
50 µM in 10 mM phosphate buffer pH 6 was analyzed. Data were
expressed in terms of [θ] R, the molar ellipticity per residue.
The propensity of the short synthetic peptides to adopt secondary
structure in solution was assessed by measurement of the circular
dichroism (CD) ellipticity values [27]. The CD spectrum represented
in Figure 2 was analyzed using the DichroWeb program. According to
the results of the analysis, the 75-99 peptides contains 31% of β-sheets
strand, 24% of β-turns and 36% of unordered conformations. The
percentage of α-helix is rather low (9%). All these data confirmed a
high flexibility of peptide (due to its content in β-structures) and
consequently a high antigenicity.
For effective immunization procedures and the generation of anti-
peptide antibodies, the use of peptide-protein conjugates is
recommended [20]. Antisera, which were collected at the end of a
standard course of immunization of rabbits against peptide conjugated
to KLH (Keyhole Limpet Hemocyanin), were tested for ELISA
characterization with peptide-ovalbumin conjugate, free peptide and
His-URG7 polypeptide (Figure 3). No reactivity using pre-immune
sera was detected, while with immune sera a strong immune response
against 75-99 peptide-ovalbumin conjugate (Figure 3A), free 75-99
peptide and His-URG7 polypeptide (Figure 3B) was observed. The
immunized rabbits developed antibodies capable of recognizing both
the 75-99 peptide chain and the entire URG7 protein obtained by
recombinant DNA technology.
The lower immunoreactivity of the antisera against the 75-99
peptides compared to that against the recombinant His-URG7
polypeptide at different antigen concentrations (Figure 3C) might be
attributed to substantially different conformation(s) of the epitope
sequence. The immune reactivity of the epitope sequence was
confirmed by western blot analysis as well (Figure 4). The recombinant
His-URG7 polypeptide was resolved by SDS-PAGE and blotted with
rabbit antisera, as described in the Materials and Methods section.
Immunoreactivity in denaturant conditions was observed at 100 ng of
polypeptide and a sera dilution of 1:3000. The band at molecular
weight greater than 17 kDa could correspond to an oligomeric form of
the polypeptide.
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Figure 3: ELISA assay with rabbit polyclonal antibodies. Pre
immune and immune serum of rabbit 1 and 2 were used for the
detection of immobilized (A) 75-99 peptide conjugated with KLH ;
(B) 1 µg/well 75-99 peptide alone (▲) and 0.2 µg/well recombinant
His-URG7 polypeptide (●); (C) reactivity of rabbit polyclonal
serum (1:7000 dilution) to different immobilized amounts of 75-99
peptide (▲) and recombinant His-URG7 polypeptide (●).
In order to verify the specificity of the antigen 75-99 peptide to
recognize human anti-URG7 antibodies, ELISA was performed
immobilizing separately the 75-99 peptide (Figure 5A) and the
recombinant His-URG7 polypeptide (Figure 5B) and using human sera
of both healthy subjects and HBV infected patients (sick). For both
antigens, box-plots in Figure 5 show a greater variability in the upper
distribution when the random sample from sick subjects is compared
with the random sample from healthy subjects. Random sample related
to the healthy subjects has a Gaussian distribution (p-value 0.50 for
75-99 peptide and p-value 0.24 for His-URG7 polypeptide), whereas
random sample related to the sick subjects does not (p-value <0.05).
Comparison of the responses between 75-99 peptide and His-URG7
polypeptide from the sick subjects shows different theoretical models
underlying the population (Kolmogorov-Smirnov test, p-value 0.03).
This is not true for the healthy subjects (Kolmogorov-Smirnov test, p-
value 0.09). The response means to the antigens are different either for
healthy subjects (p-value 0.0003) and either for sick subjects (p-value
0.03).
As suggested by the literature and according to the Gaussian
hypothesis on a healthy population, we fixed the threshold value at the
68-th percentile of the sample. This threshold is equal to 0.087 for
75-99 peptide and for His-URG7 polypeptide this threshold is below
and/or equal to 0.036. These two values are statistically different
(Kolmogorov-Smirnov test, p-value of 0.03). Therefore, the
discriminant threshold, to check the significance response to the
ELISA test, is higher for 75-99 peptide.
Figure 4: Western blot analysis of recombinant His-URG7
polypeptide. His-URG7 (lane 1, 1µg; lane 2, 0.1 µg; lane 3, 0.01 µg)
was resolved by SDS-PAGE. Protein was transferred to
nitrocellulose membranes and blotted with 1:1000 (a), 1:3000 (b)
and 1:7000 (c) rabbit antisera elicited against the 75-99 peptides.
Positions of the molecular weight standards (kDa) are indicated in
the left lane.
Figure 5: Box plot of data sampled from healthy and sick
populations. Statistical analysis are shown for 75-99 peptide in
Figure 5A and for recombinant His-URG7 polypeptide in Figure
5B. SD 0.11 for 75-99 peptides and SD 0.75 for His-URG7
polypeptide in sick subjects, while SD 0.027 for 75-99 peptide and
SD 0.021 for His-URG7 polypeptide in healthy subjects. The points
outside the box plot are outliers.
Altogether, the antigen spanning aa75-99 allows for the detection
with good sensitivity and specificity of anti-URG7 antibodies in sera of
HBV infected patients.
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Conclusion
Immuno-informatics tools and secondary structure analysis of the
synthetic peptide corresponding to the unique sequence aa75-99
belonging to the URG7 protein allowed identifying the antigenic
properties of that peptide. Sera from immunized rabbits exhibited a
strong immune response against the sequence 75-99 in an indirect
ELISA test. Finally preliminary ELISA assay against this specific
sequence of the URG7 protein allowed with good sensitivity and
specificity for the detection of anti-URG7 antibodies in sera from HBV
infected patients.
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